0
0
December 2, 2025
A next-generation influenza vaccine built on the same mRNA technology used to fight COVID-19 has demonstrated superior protection against the flu compared to standard vaccines, according to pivotal Phase 3 clinical trial results published this week in the New England Journal of Medicine (NEJM).
The findings mark a significant milestone in the quest to modernize the annual flu shot. For decades, the world has relied on influenza vaccines produced in chicken eggs—a slow, 70-year-old manufacturing process that can sometimes lead to “mismatches” between the vaccine and the circulating virus. The new data suggests that mRNA technology could offer a more agile and effective alternative, potentially reducing the global burden of seasonal influenza.
The Study: By the Numbers
The randomized, observer-blinded trial, funded by Pfizer, enrolled more than 18,000 healthy adults aged 18 to 64 during the 2022-2023 flu season. Participants were randomly assigned to receive either the experimental modified mRNA (modRNA) vaccine or a standard, licensed quadrivalent (four-strain) inactivated flu vaccine.
The results were striking. The mRNA candidate demonstrated a 34.5% higher relative vaccine efficacy against laboratory-confirmed influenza A compared to the standard flu shot.
“This is the first time we have seen head-to-head evidence of an mRNA flu vaccine outperforming the traditional standard of care in a large-scale efficacy trial,” said Dr. Kelly Lindert, a senior author of the study. “It verifies that the technology we utilized during the pandemic can be successfully pivoted to tackle seasonal respiratory viruses.”
Key statistical takeaways from the trial include:
-
Superiority against Flu A: The mRNA vaccine triggered robust immune responses against Influenza A strains (H1N1 and H3N2), which are typically responsible for the most severe flu seasons.
-
Viral Load: Among those who did get sick, participants who received the mRNA shot had lower viral loads than those who received the standard vaccine.
-
Influenza B: The trial could not determine efficacy against Influenza B strains due to very low circulation of the virus during the study period.
Why mRNA Matters: Speed and Precision
The potential shift to mRNA represents more than just a numbers game; it is a fundamental change in how we protect public health. Traditional flu vaccines take roughly six months to manufacture. Health officials must select the strains in February for a vaccine that won’t be administered until October. In that window, the virus can mutate, rendering the egg-based vaccine less effective—a phenomenon known as “egg adaptation.”
“The real promise of mRNA isn’t just about higher antibody titers; it’s about speed and fidelity,” explains Dr. William Hanage, an epidemiologist at the Harvard T.H. Chan School of Public Health, who was not involved in the study. “With mRNA, you don’t need eggs. You are giving the body the exact genetic instructions to recognize the virus as it exists in the wild. If a new strain emerges late in the summer, manufacturers could theoretically pivot and produce a matched vaccine in weeks, not months.”
The Trade-off: Reactogenicity
While the efficacy data is promising, the study also highlighted a notable trade-off: side effects. The mRNA vaccine was associated with higher rates of “reactogenicity”—temporary physical reactions to the shot.
-
Local Reactions: Approximately 70% of mRNA recipients reported pain or swelling at the injection site, compared to 43% of those who received the standard shot.
-
Systemic Symptoms: Systemic side effects like fever, headache, muscle pain, and fatigue were also more common in the mRNA group.
Importantly, safety data showed no increase in serious adverse events. Conditions of special concern, such as myocarditis (inflammation of the heart muscle), were not observed in the trial participants.
Expert Caution and Future Outlook
Despite the enthusiasm, experts urge a balanced interpretation of the results. In an accompanying editorial in the NEJM, Drs. Hana El Sahly and Robert Atmar of Baylor College of Medicine noted that while the results are a “step forward,” gaps remain.
One critical limitation is the age group. The Pfizer trial focused on adults 18 to 64. However, the flu is deadliest for adults over 65, whose aging immune systems often struggle to mount a defense even after vaccination.
“We need to see replicable data in the elderly population,” noted Dr. Hanage. “A vaccine that works beautifully in a 30-year-old immune system does not automatically translate to better protection for an 80-year-old, who needs it most.”
Competitor Moderna is also advancing its own mRNA flu candidate (mRNA-1010), having recently announced positive Phase 3 results in older adults (aged 50+), suggesting the industry is rapidly closing in on a solution for all age groups.
What This Means for You
For the average health-conscious consumer, these findings suggest that flu shots of the near future may be more effective but might pack a bit more of a punch in terms of temporary side effects.
“If you are willing to tolerate a day of feeling ‘blah’—a sore arm or a mild headache—in exchange for significantly better odds of avoiding the actual flu, which can knock you out for a week or more, that is a trade-off many patients will likely accept,” said Dr. Sarah Vane, a primary care physician in Chicago.
As regulatory bodies like the FDA review this data, it is possible that mRNA flu vaccines could become available alongside traditional options within the next year or two, giving patients a choice in how they protect themselves.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
Primary Study:
-
Fitz-Patrick, D., et al. (2025). Efficacy of a Modified mRNA Influenza Vaccine in Adults 18 to 64 Years of Age. The New England Journal of Medicine. DOI: 10.1056/NEJMoa2416779.
-
